15-Jul-2022 | Facts and Factors
According to Facts and Factors, the global anticoagulants market was valued at USD 23,817.5 million in 2021 and is predicted to increase at a CAGR of 9.01% to USD 42,756.02 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries.
According to recent studies, hypercoagulability in those infected by the coronavirus illness (COVID-19) pandemic may be one of the major causes of death worldwide. As a result, the increasing number of cases is positively influencing the need for anticoagulant medications to treat thrombosis in critically ill or hospitalized patients. Additionally, risk factors such as prolonged sitting, smoking, trauma, blood disorders, and autoimmune diseases can cause blood clotting in various sections of the body. This, combined with the rising frequency of human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, and chronic inflammation, is another key driver bolstering market expansion. Aside from that, the world's aging population is causing an increase in demand for surgical services. Surgery frequently necessitates prolonged bed rest, which raises the risk of blood clotting and the overall sales of anticoagulant medicines.
Browse the full “Anticoagulants Market Size, Share, Growth Analysis Report By Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, Others), By Route of Administration (Oral anticoagulant, Injectable anticoagulant), By Application (Atrial fibrillation & heart attack, Stroke, Deep vein embolism (PE), Others), and By Region - Global Industry Insights, Comparative Analysis, Trends, Statistical Research, Market Intelligence, and Forecast 2022 – 2028" report at https://www.fnfresearch.com/anticoagulants-market
Furthermore, rising diagnosis rates and rising demand for target therapies are propelling the industry forward. The rise of internet pharmacies is also fuelling the global demand for anticoagulant medications. However, the worldwide anticoagulants market is hampered by rigorous regulations imposed by various governments. Furthermore, the danger of side effects and difficulties connected with the use of oral anticoagulants impedes the global anticoagulants market's growth.
Segmental Overview
In terms of Drug Class, the NOACs category is currently a prominent revenue-generating segment in the anticoagulants market and is expected to dominate over the forecast period, owing to expanding NOAC adoption in developing countries and rising use of NOACs over warfarin. NOACs medications are available on market, including rivaroxaban, betrixaban, apixaban, edoxaban, and dabigatran. Furthermore, NOACs have several advantages over warfarin, including a faster onset of action, less drug and food interaction, predictable pharmacokinetic activity, a shorter half-life, and no dietary restrictions. These have contributed to the market's expansion.
In terms of Application, the atrial fibrillation & heart attack category is currently a key revenue generator and is expected to remain dominant over the projected period because of the vast target population and rising use of anticoagulants in the treatment of these disorders. However, DVT is predicted to be the fastest-growing market segment, owing to increased DVT prevalence and technical advancements in DVT diagnostics.
Regional Overview
North America accounted for almost half of the global market in the forecast period and is likely to maintain its dominance during the forecast period. This was ascribed to increased demand for novel therapies, the presence of major stakeholders, early diagnosis, enhanced healthcare infrastructure, the presence of qualified medical experts, and a larger target population. Due to growing knowledge about the therapeutic benefits of anticoagulants in disease management and the country's expanding obesity incidence, the United States accounted for the largest proportion of anticoagulants in the region. Furthermore, it has the world's highest obesity rate. Thus driving the regional market.
The Asia-Pacific area, on the other hand, is predicted to grow at the fastest rate during the projection period, owing mostly to improved healthcare infrastructure in developing nations, higher diagnosis rates, increased health awareness, and rising prevalence of cardiovascular disease and VTE. Furthermore, continuing economic development, such as the expansion of healthcare infrastructure and the improvement of healthcare awareness, has aided market growth.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 23,817.5 Million |
Projected Market Size in 2028 |
USD 42,756.02 Million |
CAGR Growth Rate |
9.01% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited GlaxoSmithKline plc., johnson & johnson, janssen Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., Sanofi S.A., and Others |
Key Segment |
By Drug Class, Route of Administration, Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Landscape
Some of the major companies operating in the anticoagulants market are Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited GlaxoSmithKline plc.,Johnson & Johnson, Janssen Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., Sanofi S.A., And among others.
The global anticoagulants market is segmented as follows:
By Drug Class
- NOACs
- Heparin & LMWH
- Vitamin K Antagonist
- Others
By Route of Administration
- Oral anticoagulant
- Injectable anticoagulant
By Application
- Atrial fibrillation & heart attack
- Stroke
- Deep vein embolism (PE)
- Others
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
